The initiation of a regulatory investigation by the NHTSA into Tesla's software update remedy for a significant recall can lead to negative public perception and potential financial implications. Regulatory probes often result in increased scrutiny, potential fines, or further recalls, all of which can adversely affect Tesla's stock price in the short term. The specific mention of post-remedy crash events and preliminary test concerns heightens the risk of negative outcomes from this investigation.